Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oligoprogression in NSCLC with Other Actionable Oncogenic Drivers Beyond EGFR and ALK: An Emerging Entity.

International journal of molecular sciences - 13 Mar 2026

Scaglione Ilaria Mariangela, Bonato Adele, Dodi Alessandra, Sposito Marco, Eccher Serena, Avancini Alice, Tregnago Daniela, Insolda Jessica, Milella Michele, Pilotto Sara, Belluomini Lorenzo

Abstract excerpt

Oligoprogressive disease (OPD) in non-small-cell lung cancer (NSCLC) is a clinical entity with peculiar behavior and treatment. OPD patients, during systemic therapy, may receive local ablative treatment (LAT) with survival benefit. The importance of OPD and the role of LAT has been comprehensively assessed in the setting of EGFR mutant and ALK-rearranged NSCLC during tyrosine kinase inhibitor (TKI) treatment,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Oncogenes

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 41898505
DOI: 10.3390/ijms27062643
PMCID: PMC13027157

Genes

LAT
ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oligoprogression in NSCLC with Other Actionable Oncogenic Drivers Beyond EGFR and ALK: An Emerging Entity.PMID 41898505Read ↗

Current Status of Multimodal Therapy for Oligometastatic Disease, Induced Oligometastatic Disease and Oligo-Progressive Disease in EGFR-Mutated Non-Small Cell Lung CancerSemantic proximity Read ↗

Targeted therapy for lung cancer: Beyond EGFR and ALK.Semantic proximity Read ↗

Management of Oligometastasis and Oligoprogression in Patients with Epidermal Growth Factor Receptor Mutation-Positive NSCLC in the Era of Third-Generation Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Clinicopathologic features and therapeutic outcomes in EGFR/ALK-aberrations NSCLC with histologic transformation.Semantic proximity Read ↗

New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).Semantic proximity Read ↗

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 InhibitorsSemantic proximity Read ↗

Complex situations in lung cancer: multifocal disease, oligoprogression and oligorecurrence.Semantic proximity Read ↗

Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options.Semantic proximity Read ↗

Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeted therapy for non-small cell lung cancer (NSCLC) in a real-world setting: A single practice experience.Semantic proximity Read ↗

Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.Semantic proximity Read ↗

SBRT for oligoprogressive oncogene addicted NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.